Publication
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerLung Adenocarcinomacivic_curation1.00
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugGefitinibcivic_curation1.00
- drugOsimertinibcivic_curation1.00
- geneRAD51civic_curation1.00
- variantRAD51 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35399574
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAD51 Fusion2 | ||||||||
| Erlotinib + OsimertinibSequential | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID12370This is a case report of 29-year-old diagnosed with metastatic adenocarcinoma of the left lung. The patient was treated with chemotherapy (cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks) an… (full text at CIViC) PMID 35399574 · Di Federico et al., 2022 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID12371A 37-year-old never smoker was diagnosed of pulmonary adenocarcinoma with mucinous pattern. FoundationOne DX1 panel detected an EGFR::RAD51 fusion and the patient was treated with first-line gefitinib… (full text at CIViC) PMID 35399574 · Di Federico et al., 2022 · Open in CIViC | civic |